Boehringer Ingelheim Establishes R&D Center in Shanghai, Enhances Early Clinical Development of New Drugs, Deepens External Innovation Collaboration
October 12, 2026 — 18:15 CST
This Data Is Locked!
This area is available only to Subscribers.
Boehringer Ingelheim announced the official completion of its newly established R&D center in Zhangjiang, Shanghai, marking a new phase in the company's research deployment in... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
